US opioid-class REMS will include certifications
22 April 2009
Sue Sutter
Please Login to read the full article.
22 April 2009
Sue Sutter
The US FDA's vision of a risk evaluation and mitigation strategy (REMS) for long-acting opioid class of products includes prescriber and pharmacist education and certifications, as well as a patient-prescriber agreement.
The FDA is seeking public comment at a May 27th-28th meeting...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
